Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Return on Sales (2020 - 2026)

Insight Molecular Diagnostics' Return on Sales history spans 6 years, with the latest figure at 0.21% for Q4 2025.

  • On a quarterly basis, Return on Sales rose 2.0% to 0.21% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.13%, a 20.0% increase, with the full-year FY2025 number at 0.13%, up 20.0% from a year prior.
  • Return on Sales hit 0.21% in Q4 2025 for Insight Molecular Diagnostics, up from 0.42% in the prior quarter.
  • Over the last five years, Return on Sales for IMDX hit a ceiling of 0.02% in Q4 2023 and a floor of 1.2% in Q4 2022.
  • Historically, Return on Sales has averaged 0.36% across 5 years, with a median of 0.22% in 2024.
  • Biggest five-year swings in Return on Sales: surged 617bps in 2021 and later tumbled -110bps in 2022.
  • Tracing IMDX's Return on Sales over 5 years: stood at 0.1% in 2021, then crashed by -1110bps to 1.2% in 2022, then skyrocketed by 98bps to 0.02% in 2023, then crashed by -1062bps to 0.23% in 2024, then increased by 9bps to 0.21% in 2025.
  • Business Quant data shows Return on Sales for IMDX at 0.21% in Q4 2025, 0.42% in Q3 2025, and 0.19% in Q2 2025.